Device Trial Radar · NCT02392078
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,153
Actual
Start
Oct 2015
Primary completion
Sep 30, 2023
Study completion Sep 30, 2023
Sponsor
- Lead sponsor
- Monteris MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 18, 2015
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 3,000 patients and up to 50 sites.
Conditions
- Metastatic Brain Tumor
- Primary Brain Tumor
- Epileptic/Seizure Foci
- Movement Disorders
Interventions
NeuroBlate SystemDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (Reportable Adverse Events)Time frame: up to 5 years or last follow up
4 more outcomes with a free account
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center
Phoenix, Arizona
25 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.